Drug intelligence / Profile preview

TGI-16

Development stage: Preclinical
Lead developer: TG ImmunoPharma
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

TGI-16 is an early-stage T-cell engager (TCE) being developed by TG ImmunoPharma for the treatment of oncology indications. As a T-cell engager, the therapeutic is designed to simultaneously bind to a tumor-associated antigen (TAA) on cancer cells and the CD3 receptor on T-cells, bridging them to trigger T-cell activation and subsequent tumor cell lysis. TGI-16 is currently in the CMC (Chemistry, Manufacturing, and Controls) development phase, utilizing TG ImmunoPharma's proprietary antibody platforms.

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on TGI-16.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TGI-16.